Project overview
SMILE aims to reduce the disease/treatment-associated side-effect burden in medulloblastoma survivors. This will be achieved by forming a unique multidisciplinary team of internationally-leading experts and future leaders, optimally positioned to initiate a pan-European network for the development/delivery of future clinical advances.
